Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DermaVir in Treatment-Naïve HIV-1
NCT00711230Phase 2Completed
- Sponsor
- Genetic Immunity
- Start
- Apr 2008
- Primary completion
- Dec 2011
- Modality
- Nanoparticles, DNA Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DermaVir in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by Genetic Immunity. Primary endpoint: Percent of participants with primary safety endpoint at 24 weeks. Started Apr 2008; status: completed.
02
Drugs
DermaVir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00711230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711230.